CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Vismodegib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01174264
NCT01174264Phase 2Completed
CompareCT.gov

Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling

National Cancer Institute (NCI)·interventional·Posted Aug 3, 2010·Updated May 19, 2017

In Brief

A Phase 2 clinical trial evaluating Pharmacological Study and Vismodegib for Malignant Neoplasm. Completed, enrolled 63 participants across 1 site.

Detailed Summary

This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 3, 2010
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 15.9 years ago

Interventions

Pharmacological Studyother

Correlative studies

Vismodegibdrug

Given PO